Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
By J. Llovet, M. Real, X. Montañá, R. Planas, S. Coll, J. Aponte, C. Ayuso, M. Sala, J. Muchart, R. Solá and 2 more. The Lancet, 2002
3,362 citations recorded by the source corpus.
Subfields: Hepatology, Surgery
View Paper: https://www.semanticscholar.org/paper/046281a1bd883cdd7120d08d257092d7b9701d28
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
- J. Llovet
- Jordi Bruix1 , 2
- Riccardo Lencioni
- V. Mazzaferro
- Amit G. Singal
- Alejandro Forner1 , 2
- L. Kulik
- Andrew X. Zhu
In Surgery
Citations in the corpus
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010, methodology): “Positive likelihood ratio MDCT Multidetector-row CT MTT Molecular targeted therapy NASH Nonalcoholic steatohepatitis PDGFR Platelet-derived growth factor receptors PIVKA-II Prothrombin induced by vitamin K absence-II RCT Randomized controlled trial RD Risk difference SPIO Superparamagnetic iron oxid”
- Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. (2010, background): “Age (y) Younger than 65 138 (47) 65 or older 153 (53) 75 or older 64 (22) Sex Male 223 (77) Female 68 (23) Ethnicity White 208 (71) Black 37 (13) Asian 29 (10) Hispanic 17 (6) Etiology Hepatitis C virus 100 (34) Alcohol 56 (19) Cryptogenic 54 (19) Hepatitis B virus 26 (9) Hepatitis C virus and alcoh”
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “Survival benefits were obtained in two studies [292,293], one of which identified treatment response as an independent predictor of survival [293].”
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019, background): “Median OS in BCLC B patients treated with TACE in RCTs has increased from 20 to 26 months because of improved patient selection with acknowledgement that Child-Pugh may not be sufficient to determine patients with expected survival benefit associated with chemoembolization.(146,147) Additionally, te”
- Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data (2016, background): “The evidence supporting the use of lipiodol TACE in the treatment of HCC comes from two metaanalyses including randomized, controlled trials (RCTs) of arterial embolization or chemoembolization versus conservative management.((7-13)) These metaanalyses identified a distinct survival benefit for lipi”